Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Optimizing Adult Vaccination Ecosystem in India
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Vaccines India
    Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate to Severe Atopic Dermatitis
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology China, France, Germany, Italy, Japan, Korea, Spain, USA
    Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
    Release Date:
    Review Process: Pfizer Internal
    Research Oncology Spain
    Optimizing Clinical Care Delivery for Patients with Multiple Myeloma Receiving Bispecific Antibodies
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology All
    Enhancing HCP Education in Maternal Vaccination
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines Saudi Arabia
    Diagnosis and Treatment of Cancer Cachexia
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology All
    Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic Diseases
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Education on Mechanism of Action of JAK3 and TEC Family Kinase Role in Alopecia Areata
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    2026 Hemophilia Fellowship – United States
    Release Date:
    Review Process: Expert Review Panel
    Fellowship Rare Disease All
    Pediatric Pneumococcal Disease and Serotype Distribution: Surveillance Studies in Saudi Arabia
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines Saudi Arabia
    Optimising Ulcerative Colitis Care: Bridging Knowledge Gaps, Integrating Biomarker-Based Strategies, and Advancing Equity
    Release Date:
    Review Process: Expert Review Panel
    Education Inflammation & Immunology Australia
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Life-Long Learning and Implementation of Education in Pain Associated with Osteoarthritis (Europe EFIC)
    Release Date:
    Partner:

    Lilly

    Review Process: Expert Review Panel
    Quality Improvement Internal Medicine Albania, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, France, Metropolitan, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Moldova, Republic of, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Slovakia (Slovak Republic), Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom
    Use of Biosimilar Agents in Inflammatory Conditions
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    Diagnosis of Invasive Fungal Infections
    Release Date:
    Review Process: Pfizer Internal
    Education Hospital Afghanistan, Albania, Algeria, American Samoa, Andorra, Angola, Anguilla, Antarctica, Antigua and Barbuda, Argentina, Armenia, Aruba, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bermuda, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Bouvet Island, Brazil, British Indian Ocean Territory, Brunei Darussalam, Bulgaria, Burkina Faso, Burundi, Cambodia, Cameroon, Canada, Cape Verde, Cayman Islands, Central African Republic, Chad, Chile, China, Christmas Island, Cocos (Keeling) Islands, Colombia, Comoros, Congo, Congo, The Democratic Republic, Cook Islands, Costa Rica, Cote D'ivoire, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Djibouti, Dominica, Dominican Republic, East Timor, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Ethiopia, Falkland Islands (Malvinas), Faroe Islands, Fiji, Finland, France, France, Metropolitan, French Guiana, French Polynesia, French Southern Territories, Gabon, Gambia, Georgia, Germany, Ghana, Gibraltar, Greece, Greenland, Grenada, Guadeloupe, Guam, Guatemala, Guinea, Guinea-bissau, Guyana, Haiti, Heard and Mc Donald Islands, Holy See (Vatican City State), Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran (Islamic Republic of), Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, Korea, Korea, Democratic People's Rep, Kuwait, Kyrgyzstan, Lao People's Democratic Republ, Latvia, Lebanon, Lesotho, Liberia, Libyan Arab Jamahiriya, Liechtenstein, Lithuania, Luxembourg, Macau, Macedonia, The Former Yugoslav, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Martinique, Mauritania, Mauritius, Mayotte, Mexico, Micronesia, Federated States o, Moldova, Republic of, Monaco, Mongolia, Montserrat, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Netherlands, Netherlands Antilles, New Caledonia, New Zealand, Nicaragua, Niger, Nigeria, Niue, Norfolk Island, Northern Mariana Islands, Norway, Oman, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Pitcairn, Poland, Portugal, Puerto Rico, Qatar, Reunion, Romania, Russia, Russian Federation, Rwanda, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadin, Samoa, San Marino, Sao Tome and Principe, Saudi Arabia, Senegal, Seychelles, Sierra Leone, Singapore, Slovakia (Slovak Republic), Slovenia, Solomon Islands, Somalia, South Africa, South Georgia and the South Sa, Spain, Sri Lanka, St. Helena, St. Pierre and Miquelon, Sudan, Suriname, Svalbard and Jan Mayen Islands, Swaziland, Sweden, Switzerland, Syrian Arab Republic, Taiwan, Tajikistan, Tanzania, United Republic of, Thailand, Togo, Tokelau, Tonga, Trinidad and Tobago, Tunisia, Turkey, Turkmenistan, Turks and Caicos Islands, Tuvalu, Uganda, Ukraine, United Arab Emirates, United Kingdom, United States Minor Outlying I, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, Virgin Islands (British), Virgin Islands (U.S.), Wallis and Futuna Islands, Western Sahara, Yemen, Yugoslavia, Zambia, Zimbabwe
    Adoption of Biosimilars in Oncology
    Release Date:
    Partner:

    The National Comprehensive Cancer Network® (NCCN)

    Review Process: Expert Review Panel
    Research Oncology USA
    Improving Disparities in Rheumatoid Arthritis Health Care in Post COVID-19 Era in memory of Cinzia Curiale
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Liechtenstein, Luxembourg, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom
    Management of Non-Communicable Diseases (NCD) for Health Care Providers
    Release Date:
    Review Process: Pfizer Internal
    Education Internal Medicine Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Holy See (Vatican City State), Hungary, Iceland, Ireland, Italy, Japan, Kazakhstan, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, The Former Yugoslav, Malta, Moldova, Republic of, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Slovakia (Slovak Republic), Slovenia, Spain, Sweden, Switzerland, Turkey, USA, Ukraine, United Kingdom
    Continuity of Care: Education for Rheumatology Patients
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    Assessment of on-time immunization coverage in children under 2 years of age in Canada
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines Canada
    Optimal Early Therapy Management in CML
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology Canada, USA
    Addressing Racial Disparities in Cancer Care
    Release Date:
    Partner: American Cancer Society
    Review Process: Expert Review Panel
    Quality Improvement Oncology USA
    Addressing Knowledge Gaps in Growth Hormone Deficiency
    Release Date:
    Review Process: Pfizer Internal
    Education Rare Disease USA
    Telehealth in Postmenopausal Patient Care
    Release Date:
    Review Process: Pfizer Internal
    Education Internal Medicine USA